Targeting epilepsy with photopharmacology in human brain tissue
Photo-activatable drugs (PDs) are rapidly emerging as precision therapeutics across biomedical research, yet their potential in epilepsy treatment has remained understudied. Given that 30% of epilepsies are medically refractory, and anti-seizure medications often cause multi-organ side-effects, PDs could break new ground. Here, we evaluate light-switchable ion-channel blockers QAQ and CQAQ, and a newly developed caged propofol (CaP), in murine brain slices, and postsurgical brain tissue from patients with epilepsy or brain tumors. In mice, we show that QAQ/CQAQ reversibly suppress neuronal firing, while photo-activated CaP prolonged inhibitory post-synaptic currents and enhanced leak current. While QAQ caused identical effects in human tissue, CQAQ unexpectedly increased firing. Activated CaP robustly suppressed epileptiform activity across species. This work establishes CaP as a tool for neuroscience and disease-related studies. Our results highlight the necessity for early human model testing in biomedical research, and showcase photopharmacology as a potential powerful approach to control human epilepsy.